International AIDS Vaccine Initiative (IAVI)
IAVI is a nonprofit scientific research organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases. Their mission is to translate scientific discoveries into affordable, globally accessible public health solutions, aiming for a world where all people have equitable access to innovative vaccines and therapeutics.
International AIDS Vaccine Initiative (IAVI)
125 Broad Street, 9th Floor, New York, NY 10004, USA
What We Do
IAVI is developing next-generation HIV vaccines to address the complexities of HIV vaccine design, including the development of broadly neutralizing antibodies (bnAbs) to prevent HIV acquisition.
IAVI collaborates with partners to develop safe, effective, and accessible TB vaccines, advancing promising candidates from discovery through clinical trials to post-licensure access.
IAVI is developing vaccine candidates for several emerging infectious diseases, utilizing proven vaccine technology to prepare for future outbreaks.
IAVI is advancing a Lassa fever vaccine candidate, focusing on end-to-end development and partnerships to establish novel vaccine programs.
IAVI is developing a vaccine candidate for the Marburg virus, utilizing innovative approaches to enhance mucosal immunity.
Services
Show More (2)Application Area
Biologics
Key People
President and CEO
Chief Operating Officer
Chief Medical Officer
ADVANCE Chief of Party and IAVI Africa Director
News & Updates
IAVI’s strong presence at the TropMed conference will showcase the expansion of our emerging infectious diseases program and enable critical dialogue with our global health peers.
IAVI leaders will chair sessions and share the latest on our emerging infectious diseases program, vaccine innovation, and more at Europe’s largest vaccine conference.
Cross-disciplinary conversations highlighted recent progress in HIV vaccine and antibody research, as well as the importance of choice and community collaboration when developing HIV prevention strategies.
Discovery medicine trials are underway to evaluate several HIV vaccine immunogens designed to prime the immune system to make broadly neutralizing antibodies.
Quarraisha and Salim Abdool Karim received the 2024 Lasker-Bloomberg Public Service Award for their work on HIV prevention, treatment, and advocacy.